NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL™ Platform

NEXT STORY
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics
PREV STORY
BioNTech Announces Full Year 2019 Financial Results and Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

electroCore, Inc. to Present at the Evercore ISI HealthCONx Conference

BASKING RIDGE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), ...

author_avatar
NASDAQ Market News

Cesca Therapeutics to Announce Financial Results for the First Quarter Ended March 31, 2018 and Host Conference Call on May 14

RANCHO CORDOVA, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or ...

author_avatar
NASDAQ Market News

OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel

author_avatar
NASDAQ Market News